RADICUT Oral Suspension 2.1% for amyotrophic lateral sclerosis (ALS, edaravone, Radicava)

Is RADICUT® Oral Suspension 2.1% effective for the treatment of amyotrophic lateral sclerosis (ALS, edaravone, Radicava)?

 

Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and atrophy throughout the body. This includes the extremities, facial muscles, and respiratory system. The cause of ALS is largely unknown but may involve genetic and environmental factors. With an incidence rate of approximately two in 100,000 people annually worldwide, it stands as one of the most prominent neuromuscular diseases. For those seeking ALS treatment, RADICUT® Oral Suspension emerges as a vital therapeutic option.

 

Advanced ALS Treatment with RADICUT® Oral Suspension

Developed by Mitsubishi Tanabe, RADICUT® Oral Suspension is formulated to offer ALS patients a convenient and effective treatment option. The active ingredient, edaravone, is a powerful free radical scavenger initially approved in Japan in April 2001 for acute cerebral infarction and later for ALS treatment in 11 countries, including the U.S., Canada, and Switzerland. ALS patients can now buy edaravone in an oral form, significantly reducing the burdens associated with intravenous administration, such as injection pain and frequent hospital visits.

 

How RADICUT® Oral Suspension Works

RADICUT® Oral Suspension contains the same active ingredient as the intravenous formulation, providing consistent therapeutic effects. Administered as a 5 ml dose once daily using an oral dosing syringe, it ensures that ALS patients receive the necessary medication without the discomfort of injections. Patients can buy RADICUT and benefit from its ease of use, which supports better compliance and an improved quality of life.

 

Proven Effectiveness of RADICUT® Oral Suspension

Scientific research underscores the effectiveness of RADICUT® Oral Suspension. A study titled “Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects” demonstrated the equivalent exposure of the 105-mg oral suspension to the 60-mg intravenous formulation. Both forms showed similar plasma concentration–time profiles, with the oral suspension even yielding higher plasma concentrations of edaravone inactive metabolites. Edaravone in both routes underwent urinary excretion, urinary excretion of unchanged edaravone was low, and urinary relative composition ratios of unchanged edaravone and metabolites were similar for both formulations. This indicates that the oral suspension is as effective as the intravenous form in delivering edaravone's therapeutic benefits, making it a reliable ALS treatment option.

 

RADICUT® Oral Suspension represents a significant advancement in the treatment of amyotrophic lateral sclerosis. Its oral formulation simplifies the administration process, reduces patient burden, and maintains the proven effectiveness of edaravone. For those looking to buy edaravone or buy RADICUT, this oral suspension offers a practical and efficient solution for managing ALS, backed by robust scientific evidence.

 

Package details: 1 bottle * 35 ml

Dosage and administration: in general, for adults, 5 ml (105 mg of edaravone) is orally administered once daily on an empty stomach.

Normally, one course consists of 28 days of administration and rest periods, and this is repeated. In the first course, the drug is administered every day for 14 days, followed by a 14-day rest period, and from the second course onwards, 10 days of administration out of the 14 days are administered, followed by a 14-day rest period.

Active components: edaravone

Therapeutic effect: Suppression of progression of functional impairment in amyotrophic lateral sclerosis (ALS)

Contraindications and precautions: Store in a dry cool place, out of reach of children. Do not use for pregnant or breastfeeding women. Do not use for the patients with severe renal insufficiency. Not recommended for use in patients with ALS severity classification of grade 4 or higher and patients with forced vital capacity reduced to less than 70% of the theoretical normal value. 

Since the plasma concentration of this drug decreases due to the influence of food, this drug should be taken after fasting for 8 hours, such as upon waking up, and food and drink other than water should be avoided for at least 1 hour after taking the drug. If fasting for 8 hours is not possible, this drug can be taken at least 4 hours after ingesting a low-fat meal or at least 2 hours after ingesting a light meal. However, this drug should be taken at least 8 hours after ingesting a high-fat meal. 

Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.